Drug intelligence / Profile preview

SIR-T STEAP2

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T STEAP2 is an investigational cell therapy being developed by Angeles Therapeutics for the treatment of prostate cancer. It is built on the proprietary Synthetic Immune Receptor (SIR) platform, which engineers T cells to provide physiological T cell receptor (TCR) signaling. This mechanism is intended to offer enhanced antigen sensitivity and superior tumor control with a reduced risk of excessive cytokine production compared to conventional CAR-T products. The therapy specifically targets Six-Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2), a cell-surface antigen highly expressed in prostate cancer. The program is currently in the IND-enabling stage of development.

Other names: SIR-T STEAP2

Targets

STEAP2 (Six-transmembrane epithelial antigen of the prostate 2)

Beyond the preview

Go deeper on SIR-T STEAP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T STEAP2.

Explore the full profile